Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Béhé

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Biopolymers|March 27, 2003
Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignanciesMartin Béhé, Thomas M Behr
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2016
Targets and probes for non-invasive imaging of β-cellsAndreas Jodal, Roger Schibli, Martin Béhé
Wiener Klinische Wochenschrift|November 7, 2007
Imaging of gastrinomas by nuclear medicine methodsMartin Béhé, Martin Gotthardt, Thomas M Behr
Cancer Biotherapy & Radiopharmaceuticals|October 25, 2002
Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settingsThomas M Behr, Martin Béhé, George Sgouros
Cancers|June 2, 2021
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin <sup>177</sup>Lu-PP-F11NNathalie M Grob, Roger Schibli, Martin Béhé, et al.
EJNMMI Research|November 19, 2013
Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic propertiesSusanne Kossatz, Rosalba Mansi, Martin Béhé, et al.
Nuclear Medicine and Biology|June 14, 2025
Comparative evaluation of radiolabeled bombesin analogs [<sup>177</sup>Lu]Lu-AMBA and [<sup>177</sup>Lu]Lu-RM2 for targeting GRPR in glioblastoma modelMichal Grzmil, Muriel Aline Spahn, Philipp Berger, et al.
EJNMMI Research|July 10, 2014
A comparison of three (67/68)Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelatorAndreas Jodal, Brigitte Lankat-Buttgereit, Maarten Brom, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 28, 2003
Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivativesMartin Béhé, Wolfgang Becker, Martin Gotthardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneysMartin Béhé, Gerald Kluge, Wolfgang Becker, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Biopolymers|March 27, 2003
Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignanciesMartin Béhé, Thomas M Behr
European Journal of Nuclear Medicine and Molecular Imaging|December 28, 2016
Targets and probes for non-invasive imaging of β-cellsAndreas Jodal, Roger Schibli, Martin Béhé
Wiener Klinische Wochenschrift|November 7, 2007
Imaging of gastrinomas by nuclear medicine methodsMartin Béhé, Martin Gotthardt, Thomas M Behr
Cancer Biotherapy & Radiopharmaceuticals|October 25, 2002
Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settingsThomas M Behr, Martin Béhé, George Sgouros
Cancers|June 2, 2021
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin <sup>177</sup>Lu-PP-F11NNathalie M Grob, Roger Schibli, Martin Béhé, et al.
EJNMMI Research|November 19, 2013
Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic propertiesSusanne Kossatz, Rosalba Mansi, Martin Béhé, et al.
Nuclear Medicine and Biology|June 14, 2025
Comparative evaluation of radiolabeled bombesin analogs [<sup>177</sup>Lu]Lu-AMBA and [<sup>177</sup>Lu]Lu-RM2 for targeting GRPR in glioblastoma modelMichal Grzmil, Muriel Aline Spahn, Philipp Berger, et al.
EJNMMI Research|July 10, 2014
A comparison of three (67/68)Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelatorAndreas Jodal, Brigitte Lankat-Buttgereit, Maarten Brom, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 28, 2003
Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivativesMartin Béhé, Wolfgang Becker, Martin Gotthardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneysMartin Béhé, Gerald Kluge, Wolfgang Becker, et al.
Pageof 6